TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

Detalles Bibliográficos
Autores principales: Schimmer, Roman R., Kovtonyuk, Larisa V., Klemm, Nancy, Fullin, Jonas, Stolz, Sebastian M., Mueller, Jan, Caiado, Francisco, Kurppa, Kari J., Ebert, Benjamin L., Manz, Markus G., Boettcher, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198927/
https://www.ncbi.nlm.nih.gov/pubmed/35026842
http://dx.doi.org/10.1182/bloodadvances.2021005859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198927/
https://www.ncbi.nlm.nih.gov/pubmed/35026842
http://dx.doi.org/10.1182/bloodadvances.2021005859

Ejemplares similares